[Management and treatment of ulcerative colitis. 3. Immunosuppressive agents]. 2009

Haruhiko Ogata, and Toshifumi Hibi

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Haruhiko Ogata, and Toshifumi Hibi
November 1995, Journal of gastroenterology,
Haruhiko Ogata, and Toshifumi Hibi
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
Haruhiko Ogata, and Toshifumi Hibi
March 1997, Bailliere's clinical gastroenterology,
Haruhiko Ogata, and Toshifumi Hibi
March 1989, Gastroenterology clinics of North America,
Haruhiko Ogata, and Toshifumi Hibi
January 1978, Progress in pediatric surgery,
Haruhiko Ogata, and Toshifumi Hibi
September 1981, The American journal of gastroenterology,
Haruhiko Ogata, and Toshifumi Hibi
January 1972, Vutreshni bolesti,
Haruhiko Ogata, and Toshifumi Hibi
January 1971, Medicinski glasnik,
Haruhiko Ogata, and Toshifumi Hibi
June 1972, Orvosi hetilap,
Haruhiko Ogata, and Toshifumi Hibi
February 1976, La Clinica terapeutica,
Copied contents to your clipboard!